1. This study evaluated the predictive value of the consensus Immunoscore in 1885 patients with AJCC/UICC-TNM stage 1-II Colon Cancer from North American, European, and Asian care centers.
2. The results showed that the immunity of early-stage CC patients, more than cancer cell-associated parameters, predicts outcome for stage 1/2 patients.
3. The Immunoscore reliably diagnoses low immune cell infiltrated patients at risk of relapse, that would benefit from a more frequent and detailed medical monitoring.
The article is generally reliable and trustworthy as it provides evidence to support its claims and presents both sides of the argument equally. It is also well written and easy to understand. However, there are some potential biases that should be noted. For example, the study only included 1885 patients which may not be representative of all colon cancer cases worldwide. Additionally, the study was conducted by an international consortium led by the Society for Immunotherapy of Cancer which could lead to bias in favor of their own product or services. Furthermore, there is no mention of possible risks associated with using the Immunoscore as a prognostic tool or any discussion on how it could be improved in future studies. Finally, while the article does provide evidence to support its claims, it does not explore any counterarguments or present any alternative perspectives on the topic which could have been beneficial for readers to consider when evaluating this research.